Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart

Rhea-AI Summary

Sonoma Pharmaceuticals (Nasdaq:SNOA) announced the U.S. retail launch of its advanced HOCl-based burn relief hydrogel in CVS and Walmart on March 24, 2026. The OTC hydrogel is indicated for minor burns and skin irritations and is marketed via a U.S.-based distribution partner.

This is Sonoma's first large-scale consumer burn product, following its 2025 diaper rash hydrogel retail rollout, and complements the company's professional wound and burn care portfolio while leveraging strategic partnerships for mass‑market distribution.

Market Reality Check

Price: $2.34 Vol: Volume of 32,190 shares i...

high vol

$2.34 Last Close

Volume Volume of 32,190 shares is about 2.24x the 20-day average of 14,358, indicating heightened pre-news activity. high

Technical Shares at $2.55 are trading below the 200-day MA of $3.53 and remain 63.15% under the 52-week high.

Peers on Argus

SNOA was up 4.94% ahead of the launch. Peers showed mixed moves: EVOK +0.18%, YC...

1 Up

SNOA was up 4.94% ahead of the launch. Peers showed mixed moves: EVOK +0.18%, YCBD +6.81%, IMCC +9.63%, while SBFM and BFRI fell 1.92% and 3.18%, respectively, pointing to stock-specific drivers.

Historical Context

5 past events · Latest: Mar 18 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 18	OTC line launch	Positive	+2.9%	Launch of Aquanil AD HOCl dermatology products for sensitive skin OTC.
Feb 10	Earnings update	Positive	+1.4%	Q3 FY26 revenue and margin growth with improved EBITDAS loss.
Jan 28	Leadership changes	Neutral	-1.5%	Board refresh and new SVP of Regulatory, Quality and Product Development.
Nov 13	Dermatology endorsement	Positive	-3.8%	Reliefacyn hydrogel earned National Rosacea Society Seal of Acceptance.
Nov 06	Conference exhibit	Positive	+0.8%	Participation at MEDICA 2025 showcasing HOCl-based scar and skin products.

Pattern Detected

Recent product and branding news often saw modest positive reactions, though one positive dermatology endorsement in late 2025 coincided with a negative move, showing occasional divergence.

Recent Company History

Over the last six months, Sonoma has steadily built its dermatology and OTC footprint. On Nov 6, 2025, it highlighted global HOCl products at MEDICA 2025. On Nov 13, 2025, its Reliefacyn hydrogel received the National Rosacea Society Seal, along with prior eczema and psoriasis endorsements. Governance and R&D leadership were refreshed on Jan 28, 2026. Earnings on Feb 10, 2026 showed revenue rising to $4.3M for Q3. On Mar 18, 2026, Sonoma launched the Aquanil AD sensitive-skin line, reinforcing its consumer-focused HOCl strategy ahead of today’s burn hydrogel launch.

Market Pulse Summary

This announcement expands Sonoma’s HOCl portfolio into a nationwide burn relief hydrogel placement a...

Analysis

This announcement expands Sonoma’s HOCl portfolio into a nationwide burn relief hydrogel placement at CVS and Walmart, following earlier OTC dermatology launches. The move continues a shift from purely professional channels to scalable consumer retail partnerships. Recent filings showed higher revenue but ongoing losses and going-concern language, so investors may watch how this product contributes to sales traction, margin trends, and cash generation relative to prior launches like Aquanil AD and diaper rash hydrogel in 2025.

Key Terms

hypochlorous acid, hocl, hydrogel

3 terms

hypochlorous acid medical

"glo bal healthcare leader in hypochlorous acid (HOCl) technology, today announced"

A mild, naturally occurring chemical formed when chlorine dissolves in water that acts as a fast-acting disinfectant and antiseptic. Think of it like a gentle, short-lived version of bleach that kills bacteria and viruses without strong fumes or persistent chemical residue. Investors watch it because demand, regulatory approvals, production capacity and safety perceptions directly affect sales in cleaning, healthcare and water-treatment markets, influencing product lines and revenue.

hocl medical

"global healthcare leader in hypochlorous acid (HOCl) technology, today announced"

Hypochlorous acid (HOCl) is a weak, fast‑acting disinfectant chemical that is produced by the immune system and formulated for use in wound care, surface sanitizers, and medical devices. Investors watch HOCl products because their safety profile, regulatory approvals, and manufacturing scalability determine how widely they can replace harsher cleaners or be adopted in healthcare and consumer markets — think of it as a gentler, quick‑acting sanitizer that can open or close market opportunities.

hydrogel medical

"retail launch of its advanced HOCl-based burn relief hydrogel in CVS and Walmart"

A hydrogel is a soft, jelly-like material made mostly of water combined with a network of flexible, supportive molecules. Its unique ability to hold large amounts of water while remaining stable makes it useful in various medical, industrial, and consumer applications. For investors, innovations involving hydrogels can signal growth opportunities in sectors like healthcare, biotechnology, and advanced materials.

AI-generated analysis. Not financial advice.

BOULDER, CO / ACCESS Newswire / March 24, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader in hypochlorous acid (HOCl) technology, today announced the U.S. retail launch of its advanced HOCl-based burn relief hydrogel in CVS and Walmart stores nationwide.

The hydrogel is indicated for the management of minor burns and skin irritations. Its gentle, non-irritating formulation is designed to help soothe damaged skin and support the natural healing process, making it well-suited for everyday consumer use, including seasonal sunburn care.

This launch represents Sonoma's first large-scale consumer-focused burn relief product, building on the Company's established presence in professional healthcare settings, where its HOCl-based solutions have long been used in advanced wound and burn care protocols. Sonoma previously demonstrated its ability to translate clinically proven technologies into scalable consumer offerings through the launch of its diaper rash hydrogel in mass retail in 2025.

The product is being commercialized through one of Sonoma's U.S.-based partners that distributes through CVS and Walmart, in line with the Company's strategy to leverage strategic partnerships to expand its presence across major retail channels while maintaining focus on innovation, regulatory compliance, and manufacturing excellence.

"We are excited to expand further into the consumer over-the-counter market with the introduction of our advanced burn relief hydrogel in leading U.S. retailers," said Amy Trombly, Chief Executive Officer of Sonoma Pharmaceuticals. "This launch builds on the strong foundation established by our prior consumer product success and reflects growing consumer awareness of hypochlorous acid as a safe and effective skincare solution. We believe this product is well-positioned to meet increasing demand for clinically-backed, gentle solutions for everyday skin concerns."

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals is a global healthcare company focused on developing and manufacturing stabilized hypochlorous acid (HOCl) products for medical, veterinary, and consumer applications. The Company's patented HOCl technology platform is designed to provide safe, effective, and environmentally friendly solutions for a wide range of indications, including wound care, dermatological conditions, and burn treatment. With integrated custom packaging and branding capabilities and multi-country regulatory expertise, Sonoma supports distribution partners in 55 countries worldwide and is actively expanding its global distributor network. The company's principal office is in Boulder, Colorado, with high-capacity manufacturing operations in Guadalajara, Mexico, and European commercial headquarters in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs, fund further development, the ability to meet a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.

Sonoma Pharmaceuticals™ and Microcyn^® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.

Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
ir@sonomapharma.com

Website: www.sonomapharma.com

Follow us on LinkedIn: https://www.linkedin.com/company/sonoma-pharmaceuticals

Follow us on Instagram: https://www.instagram.com/sonomapharma_us/

Follow us on Facebook: https://www.facebook.com/sonomapharma/

SOURCE: Sonoma Pharmaceuticals, Inc.

View the original press release on ACCESS Newswire

FAQ

What is Sonoma Pharmaceuticals (SNOA) launching in CVS and Walmart on March 24, 2026?

Sonoma is launching an advanced HOCl-based burn relief hydrogel for minor burns and skin irritations. According to the company, the OTC product is positioned for everyday consumer use, including seasonal sunburn care, and will be distributed through a U.S.-based retail partner.

How is the SNOA burn relief hydrogel being distributed to U.S. consumers?

The product is being commercialized through a U.S.-based partner that supplies CVS and Walmart nationwide. According to the company, this partnership leverages established retail channels to scale consumer availability across major stores.

What medical uses does the Sonoma (SNOA) burn relief hydrogel serve?

The hydrogel is indicated for management of minor burns and skin irritations and to support natural healing. According to the company, its gentle, non-irritating HOCl formulation is intended for everyday topical relief, including sunburn care.

How does the new SNOA retail launch relate to Sonoma's prior consumer products?

This launch follows Sonoma's 2025 mass-retail diaper rash hydrogel and reflects repeat consumer commercialization. According to the company, the new burn product builds on prior success translating clinical HOCl technology into scalable consumer offerings.

What does Sonoma say about the strategic importance of the March 24, 2026 retail launch for SNOA shareholders?

Sonoma describes the launch as expansion into the over-the-counter consumer market via major retailers. According to the company, this supports its strategy of using partnerships to increase retail presence while focusing on innovation and regulatory compliance.